IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (FOLD). Investors who purchased or otherwise acquired shares between September 15, 2015 and October 1, 2015, inclusive (the “Class Period”) are encouraged to contact the Firm immediately to discuss their legal options.
If you purchased shares of Amicus during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, on October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year.
If you purchased shares of Amicus during the Class Period you have until December 7, 2015 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.